Review
Biochemistry & Molecular Biology
Jana Tchekalarova, Rumiana Tzoneva
Summary: Aging and neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are linked by common features like mitochondrial dysfunction and protein aggregation. The rising costs of caring for elderly patients with these diseases is a major issue in today's demographic crisis. Oxidative stress and imbalanced antioxidant defense system play crucial roles in age-related neurodegeneration, and diminished melatonin release with aging further increases susceptibility to these diseases. Understanding the underlying mechanisms and melatonin's role is important for developing precise treatment strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Xinyu Hu, Jingwen Li, Xinyi Wang, Hanshu Liu, Tao Wang, Zhicheng Lin, Nian Xiong
Summary: Parkinson's disease (PD) is a complex disorder with non-motor symptoms, including sleep disorders. Melatonin, with its regulatory effects, is expected to be a potential treatment for sleep disorders in PD. Ongoing clinical trials highlight its therapeutic effects in PD.
Review
Cell Biology
Md Farhad Hossain, Ni Wang, Ruijun Chen, Siwen Li, Jaydeep Roy, Md Giash Uddin, Zhong Li, Lee Wei Lim, You-Qiang Song
Summary: Melatonin plays crucial roles in Alzheimer's disease by promoting autophagy, improving sleep quality, and counteracting oxidative stress. The therapeutic potential of melatonin in AD may involve its multifunctional properties.
AGEING RESEARCH REVIEWS
(2021)
Article
Genetics & Heredity
Christos M. Polymeropoulos, Justin Brooks, Emily L. Czeisler, Michaela A. Fisher, Mary M. Gibson, Kailey Kite, Sandra P. Smieszek, Changfu Xiao, Sarah H. Elsea, Gunther Birznieks, Mihael H. Polymeropoulos
Summary: The study confirmed that tasimelteon significantly improved sleep quality and total sleep time in patients with Smith-Magenis syndrome.
GENETICS IN MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Jaydeep Roy, Ka Chun Tsui, Jonah Ng, Man-Lung Fung, Lee Wei Lim
Summary: Alzheimer's disease is a neurodegenerative disorder characterized by pathological markers and symptoms. Studies suggest that melatonin may help improve AD pathology and restore cognitive function.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Clinical Neurology
Ying Yu, Yan Chen, Long Ma, You-Yang Qu, Yu-Nong Li, Ying Peng, Yu-Lan Zhu, Jia He, Hai-Yan Gou, Yan-Mei Zhu
Summary: This study evaluated the effect of agomelatine therapy and cognitive behavior therapy on DSWPD in young adults. The results showed that agomelatine therapy can improve sleep-wake rhythm, and combining with cognitive behavior therapy may help to maintain altered sleep rhythms.
BEHAVIORAL SLEEP MEDICINE
(2023)
Review
Biology
Sumire Matsumoto, Tomomi Tsunematsu
Summary: Protein misfolding and aggregation are associated with various neurodegenerative diseases like AD and PD. Sleep impairments in these diseases can serve as both accompanying symptoms and potential biomarkers for early diagnosis. The relationship between sleep disturbances and neurodegenerative diseases is a topic of interest for future research and potential treatment strategies.
Review
Geriatrics & Gerontology
Hongxia Ma, Junqiang Yan, Wenjie Sun, Menghan Jiang, Yongjiang Zhang
Summary: Melatonin can significantly improve the subjective and objective sleep quality of patients with PD with good safety and tolerability. However, there was no significant improvement in excessive daytime sleepiness assessed by the Epworth Sleepiness Scale (ESS). Melatonin could be considered an effective treatment for insomnia in patients with PD.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Pharmacology & Pharmacy
Behnaz Gholizadeh Niari, Parisa Adimi Naghan, Saghar Barati, Raha Eskandari, Farzaneh Dastan
Summary: This study aimed to evaluate the effects of agomelatine on polysomnography parameters in patients with obstructive sleep apnea (OSA). The results showed that agomelatine administration can improve total sleep time, sleep efficiency, and the percentage of patients' awakening in OSA patients.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
(2022)
Review
Neurosciences
A. H. M. Safayet Ullah Prodhan, Cinzia Cavestro, Mohammad Amjad Kamal, Mohammad Asiful Islam
Summary: Alzheimer's disease (AD) patients commonly experience sleep disturbances (SD), with studies suggesting that decreased melatonin levels may exacerbate AD symptoms. Exogenous melatonin shows potential for treatment, but there is still debate regarding its efficacy and optimal usage. Further extensive trials are needed to determine the effectiveness of melatonin in treating SD in AD.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
(2021)
Article
Physiology
Riccardo Cremascoli, Davide Sparasci, Gianluca Giusti, Stefania Cattaldo, Elisa Prina, Fausto Roveta, Francesco Bruno, Cristina Ghezzi, Silvia Cerri, Marta Picascia, Sara Bernini, Elena Sinforiani, Michele Terzaghi, Lorenzo Priano, Alessandro Mauro, Raffaele Manni
Summary: This study investigates the effects of light therapy on sleep quality, mood, and cognition in patients with mild/moderate Alzheimer's disease. It is shown that light therapy tailored to the individual's circadian phase can induce a circadian phase shift, improve subjective sleep quality and cognitive performance, and shorten the time between dim light melatonin onset and falling asleep.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Geriatrics & Gerontology
Xiao-bo Yang, Heng-bing Zu, Yong-fei Zhao, Kai Yao
Summary: Agomelatine can improve cognitive impairment and ameliorate AD-like pathology in APP/PS1 mice by activating DHCR24 signaling and inhibiting Akt/mTOR and Hes1/Notch1 signaling pathways. It may become a promising drug candidate in the therapy of Alzheimer's disease.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Food Science & Technology
Yujie Chen, Wuke Yuan, Qi Xu, Manju B. Reddy
Summary: Parkinson's disease (PD) and Alzheimer's disease (AD) are common neurodegenerative disorders with shared molecular mechanisms, and there is currently no effective treatment. However, research suggests that consuming phytochemicals may help delay the progression of these diseases.
JOURNAL OF FUNCTIONAL FOODS
(2023)
Article
Clinical Neurology
Fatemeh Hadi, Elmira Agah, Samaneh Tavanbakhsh, Zahra Mirsepassi, Seyed Vahid Mousavi, Negin Talachi, Abbas Tafakhori, Vajiheh Aghamollaii
Summary: This study compared the safety and efficacy of trazodone, melatonin, and clonazepam in improving sleep quality in patients with Parkinson's disease. The results showed that all three drugs were well-tolerated and effective in improving sleep quality in patients with PD.
NEUROLOGICAL SCIENCES
(2022)
Review
Neurosciences
Mohammad-Ali Samizadeh, Hamed Fallah, Mohadeseh Toomarisahzabi, Fereshteh Rezaei, Mehrsa Rahimi-Danesh, Shahin Akhondzadeh, Salar Vaseghi
Summary: Parkinson's disease (PD) is a common neurodegenerative disease with sleep disturbances, including REM behavior disorder (RBD). Melatonin, the principal hormone secreted by the pineal gland, has therapeutic effects on sleep disturbances but its molecular mechanisms in RBD treatment are unknown.